Misleading serum free thyroxine results during low molecular weight heparin treatment

Clinical Chemistry

Volumn 44, Issue 5, 1998, Pages 1002-1007

  Stevenson, Heather P ^a   Archbold, G Pooler R ^b   Johnston, Paul ^b   Young, Ian S ^b   Sheridan, Brian ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; THYROXINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; LIPOLYSIS; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID FUNCTION TEST; THYROXINE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031948511     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.5.1002     Document Type: Article

References (17)

1. Diver MJ, Jones PJ, Hughes JG, Hipkin U, West CR. Effect of preanalytical conditions on measurements of free thyroxine and total triiodothyronine [Letter]. Clin Chem 1996;42:1124.
2. Persson, E, Nordenström J, Hagenfeldt L, Nilsson-Ehle P. Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment. Thromb Res 1987;46: 697-704.
3. Bayer MF. Effect of heparin on serum free thyroxine linked to post-heparin lipolytic activity. Clin Endocrinol 1983;19:591-6.
4. Wang YS, Hershman JM, Smith V, Pekary AE. Effect of heparin on free thyroxin as measured by equilibrium dialysis and ultrafiltration. Clin Chem 1986;32:700.
5. Jain R, Uy HL. Increase in serum free thyroxine levels related to intravenous heparin treatment. Ann Intern Med 1996;12:74-5.
6. Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects. Folia Haematol 1989;116:967-80.
7. Myrmel T, Larsen TS, Reikeras O. Lipolytic effect of low-molecular-weight-heparin (Fragmin) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement. Scand J Clin Lab Invest 1992;52:741-5.
8. Wilson R, Gordon D, Johnstone, RV, Johnstone P, Beastall GH, Thomson JA. The parallel effects of a very low molecular weight heparin (CY222) on Anti Xa activity and thyroid hormone levels in blood. Scott Med J 1987;32:76-8.
9. Juame JC, Mendel CM, Frost PH, Greenspan FS, Laughton CW. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum free thyroxine concentrations as measured by equilibrium dialysis. Thyroid 1996;6:79-83.
10. Nagayama I, Yamamoto K, Saito K, Kuzuya T, Saito T. Subject-based reference values in thyroid function tests. Endocrine J 1993;40:557-62.
11. Fisher DA. Physiological variations in thyroid hormones: physiological and pathophysiological considerations. Clin Chem 1996;42: 135-9.
12. Keffer JH. Preanalytical considerations in testing thyroid function. Clin Chem 1996;42:125-34.
13. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention of thromboembolic disorders. Drugs 1992;44:465-97.
14. Christofides ND, Sheehan CP. Enhanced chemiluminescence labeled-antibody immunoassay (Amerlite-MAB) for free thyroxine: design, development and technical validation. Clin Chem 1995; 41:17-23.
15. Faber J, Waetjen I, Siersbaek-Nielsen K. Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin. Clin Chim Acta 1993;223:159-67.
16. Liewendahl K. Thyroid function tests: performance and limitations of current methodologies. Scand J Clin Lab Invest 1992;52:435-45.
17. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 1987;65:1259-64.-